Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2023-12-21 00:00:00 ET · period of report 2023-12-19 · accession 0001213900-23-097671 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-21 | 2023-12-19+ | MLTX | Bodenstedt Matthias | CFO | S - Sale | $59.17 | -100.0K | 520.9K | -16% | -$5.92M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2023-12-19 | S | D | 94,736 | $59.22 | 526,167 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.655 to $60.13. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Class A ordinary shares, par value $0.0001 per share | 2023-12-20 | S | D | 5,264 | $58.34 | 520,903 | D | — | — | (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $57.53 to $59.27. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |